Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis

This study has been completed.
Sponsor:
Information provided by:
Incara Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00033943
First received: April 16, 2002
Last updated: June 23, 2005
Last verified: October 2002
  Purpose

This study will evaluate the effectiveness and safety of the experimental compound OP2000 (deligoparin) in patients with active ulcerative colitis. Patients eligible for this study will have received (and will continue to receive) stable doses of aminosalicylates (oral, enema and/or suppository), if tolerated. OP2000 is an ultra low molecular weight heparin with anticoagulant (blood thinning) and anti-inflammatory actions that may be of benefit for the treatment of ulcerative colitis.


Condition Intervention Phase
Ulcerative Colitis
Drug: deligoparin
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Two Dosage Levels of OP2000 (75 Mg and 125 Mg) Administered Once Daily by Subcutaneous Injection for the Treatment of Active Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Incara Pharmaceuticals:

Estimated Enrollment: 270
Study Start Date: January 2001
Estimated Study Completion Date: September 2002
Detailed Description:

This is a double-blind, placebo-controlled, research study to evaluate the effectiveness and safety of the experimental compound OP2000 (deligoparin) in patients with active ulcerative colitis. Patients eligible for this study will have received (and will continue to receive) stable doses of aminosalicylates (oral, enema and/or suppository), if tolerated. OP2000 is an ultra low molecular weight heparin with anticoagulant (blood thinning) and anti-inflammatory actions that may be of benefit for the treatment of ulcerative colitis. Patients will be randomized (assigned by chance like the toss of a coin) to receive 75 mg OP2000, 125 mg OP2000, or placebo once daily for 6 weeks. Study drug will be administered by subcutaneous (under the skin) injection and patients will be taught how to self-administer these injections. Following an initial Screening Visit, eligible patients will return to the clinic for initiation of study treatment and then again for follow-up visits after 1, 2, 4 and 6 weeks of treatment. A follow-up telephone call will be scheduled 2 months (and possibly also 4 and 6 months) after completing study treatment. Study procedures will include a flexible sigmoidoscopy at the Screening Visit and at the Week 6 visit.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of ulcerative colitis at least 3 months with biopsy and colonoscopy confirmation.
  • Treatment with aminosalicylates at least 28 days, if tolerated.
  • Duration of current flare-up at least 7 days.
  • Must be able to self administer once-daily subcutaneous (under the skin) injections of study drug.

Exclusion Criteria:

  • Disease limited to the rectum.
  • Toxic megacolon.
  • The use of anticoagulant drugs.
  • A history of any bleeding disorder.
  • A history of heparin-induced thrombocytopenia.
  • Evidence of liver or kidney impairment.
  • Women who are pregnant or breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033943

  Show 33 Study Locations
Sponsors and Collaborators
Incara Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00033943     History of Changes
Other Study ID Numbers: OP201
Study First Received: April 16, 2002
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on July 31, 2014